{"log_id": 250013234520922938, "direction": 0, "words_result_num": 35, "words_result": [{"probability": {"variance": 0.000614, "average": 0.991114, "min": 0.863127}, "location": {"width": 746, "top": 253, "height": 35, "left": 267}, "words": "在6个月的对照试验中,托珠单抗8mg/kg+ DMARD组患者与安慰剂+ DMARD组患者"}, {"probability": {"variance": 0.000572, "average": 0.993421, "min": 0.846634}, "location": {"width": 786, "top": 292, "height": 35, "left": 227}, "words": "中感染事件的发生率分别为127例/100病例年与112例100病例年。在全部暴露人群中"}, {"probability": {"variance": 0.00044, "average": 0.992242, "min": 0.887342}, "location": {"width": 578, "top": 334, "height": 33, "left": 226}, "words": "托珠单抗+ DMARD组总体感染事件的发生率为108例/100病例年"}, {"probability": {"variance": 0.004596, "average": 0.98563, "min": 0.580697}, "location": {"width": 745, "top": 371, "height": 35, "left": 268}, "words": "该项6个月的对照试验还显示,托珠单抗8mg/kg+ DMARD组严重感染(细菌、病毒"}, {"probability": {"variance": 4.5e-05, "average": 0.980111, "min": 0.973375}, "location": {"width": 30, "top": 337, "height": 62, "left": 1149}, "words": "监正"}, {"probability": {"variance": 0.001328, "average": 0.983112, "min": 0.82552}, "location": {"width": 785, "top": 410, "height": 34, "left": 229}, "words": "和真菌)的发生率为5.3例100病例年,而安慰剂+ DMARD组为3.9例/100病例年。在单"}, {"probability": {"variance": 0.003769, "average": 0.978871, "min": 0.642074}, "location": {"width": 786, "top": 450, "height": 33, "left": 229}, "words": "药治疗试验中,托珠单抗组严重感染的发生率为3.6例/100病例年,而MTX组为1.5例"}, {"probability": {"variance": 5.7e-05, "average": 0.992667, "min": 0.981306}, "location": {"width": 105, "top": 498, "height": 23, "left": 229}, "words": "100病例年"}, {"probability": {"variance": 0.003937, "average": 0.983337, "min": 0.691407}, "location": {"width": 746, "top": 528, "height": 34, "left": 269}, "words": "在全部暴露人群中,严重感染的总体发生率为4.7例/100病例年。报告的严重感染"}, {"probability": {"variance": 1e-05, "average": 0.998448, "min": 0.982903}, "location": {"width": 757, "top": 567, "height": 34, "left": 238}, "words": "(其中一些含致死性结局)包括肺炎、蜂窝织炎、带状疱疹、胃肠炎、憩室炎、脓毒症"}, {"probability": {"variance": 4e-06, "average": 0.998841, "min": 0.990666}, "location": {"width": 401, "top": 611, "height": 27, "left": 230}, "words": "细菌性关节炎。还报告了一些机会性感染病例"}, {"probability": {"variance": 0, "average": 0.999632, "min": 0.998958}, "location": {"width": 83, "top": 652, "height": 25, "left": 272}, "words": "胃肠穿孔"}, {"probability": {"variance": 0.000132, "average": 0.996583, "min": 0.927799}, "location": {"width": 743, "top": 683, "height": 36, "left": 272}, "words": "在6个月的临床对照试验中,接受托珠单抗治疗患者的胃肠穿孔的总体发生率为0.26"}, {"probability": {"variance": 0.005437, "average": 0.981658, "min": 0.515567}, "location": {"width": 781, "top": 722, "height": 37, "left": 237}, "words": "例/100病例年。在全部暴露人群中,胃肠穿孔的总体发生率为0.28例/100病例年。在托"}, {"probability": {"variance": 7e-06, "average": 0.998379, "min": 0.986232}, "location": {"width": 768, "top": 763, "height": 34, "left": 232}, "words": "珠单抗治疗报告的胃肠穿孔中,一般将其报告为憩室炎并发症(包括全身化脓性腹膜炎"}, {"probability": {"variance": 0.004476, "average": 0.971775, "min": 0.758908}, "location": {"width": 230, "top": 808, "height": 25, "left": 235}, "words": "下消化道穿孔、瘘和脓肿)"}, {"probability": {"variance": 0, "average": 0.999613, "min": 0.999179}, "location": {"width": 83, "top": 849, "height": 24, "left": 275}, "words": "输液反应"}, {"probability": {"variance": 3e-06, "average": 0.9987, "min": 0.990029}, "location": {"width": 746, "top": 879, "height": 36, "left": 275}, "words": "在6个月的对照试验中,报告的与输液相关的不良反应(发生在输液期间或完成输液"}, {"probability": {"variance": 0.003199, "average": 0.980565, "min": 0.657835}, "location": {"width": 787, "top": 918, "height": 37, "left": 234}, "words": "24小时内)在托珠单抗8mg/kg+ DMARD组为6.9%,在安慰剂+ DMARD组为5.1%。在"}, {"probability": {"variance": 4e-06, "average": 0.998873, "min": 0.988681}, "location": {"width": 785, "top": 958, "height": 35, "left": 236}, "words": "输液期间发生的主要不良反应为高血压发作,而在完成输液24小时内发生的主要不良反"}, {"probability": {"variance": 9e-06, "average": 0.998625, "min": 0.987584}, "location": {"width": 556, "top": 1001, "height": 32, "left": 236}, "words": "应为头痛和皮肤反应(如皮疹,荨麻疹)。这些反应不影响治疗"}, {"probability": {"variance": 0.001389, "average": 0.990614, "min": 0.761878}, "location": {"width": 739, "top": 1037, "height": 36, "left": 283}, "words": "3778名患者中共有6名出现速发过敏反应,但4mg/kg剂量组速发过敏反应的发生率"}, {"probability": {"variance": 5.6e-05, "average": 0.997184, "min": 0.953848}, "location": {"width": 788, "top": 1078, "height": 37, "left": 236}, "words": "比8mg/kg剂量组高数倍。在3778例接受托珠单抗治疗的双盲对照和开放性临床研究中发"}, {"probability": {"variance": 0.001664, "average": 0.992202, "min": 0.747517}, "location": {"width": 787, "top": 1115, "height": 37, "left": 237}, "words": "生了13例与托珠单抗相关的、有临床意义的超敏反应,需立即停止治疗(发生率为"}, {"probability": {"variance": 4e-06, "average": 0.998317, "min": 0.991437}, "location": {"width": 791, "top": 1155, "height": 35, "left": 237}, "words": "03%)。这些反应一般发生在第2至第5次输注托珠单抗期间(见【注意事项】的一般事"}, {"probability": {"variance": 2.6e-05, "average": 0.992782, "min": 0.98581}, "location": {"width": 70, "top": 1204, "height": 23, "left": 243}, "words": "项部分)"}, {"probability": {"variance": 3e-06, "average": 0.99827, "min": 0.995187}, "location": {"width": 82, "top": 1241, "height": 24, "left": 283}, "words": "免疫原性"}, {"probability": {"variance": 3e-06, "average": 0.998735, "min": 0.99204}, "location": {"width": 745, "top": 1273, "height": 34, "left": 282}, "words": "在6个月的对照临床试验中,共2876名患者接受了抗托珠单抗抗体的检测。有46名"}, {"probability": {"variance": 0.000434, "average": 0.993141, "min": 0.88937}, "location": {"width": 787, "top": 1311, "height": 36, "left": 241}, "words": "患者(1.6%)抗托珠单抗抗体阳性,其中有5人因发生了药物相关的超敏反应而退出研究"}, {"probability": {"variance": 0.000188, "average": 0.992858, "min": 0.954553}, "location": {"width": 312, "top": 1356, "height": 30, "left": 244}, "words": "30名(1.1%)患者产生了中和抗体"}, {"probability": {"variance": 3e-06, "average": 0.998197, "min": 0.995404}, "location": {"width": 85, "top": 1397, "height": 25, "left": 284}, "words": "恶性肿瘤"}, {"probability": {"variance": 0.000104, "average": 0.996911, "min": 0.936497}, "location": {"width": 738, "top": 1430, "height": 34, "left": 284}, "words": "在24周对照试验期间,在托珠单抗组诊断出15例恶性肿瘤,在对照组诊断出8例恶"}, {"probability": {"variance": 0.006727, "average": 0.953004, "min": 0.644134}, "location": {"width": 875, "top": 1446, "height": 67, "left": 243}, "words": "性肿瘤。托珠单抗组(132例事件00患者年)与安慰剂+ -DMARD组(137例事份"}, {"probability": {"variance": 3e-06, "average": 0.9983, "min": 0.994983}, "location": {"width": 282, "top": 1514, "height": 26, "left": 245}, "words": "患者年)的暴露调整发生率相似"}, {"probability": {"variance": 4.3e-05, "average": 0.997485, "min": 0.965614}, "location": {"width": 548, "top": 1550, "height": 28, "left": 286}, "words": "在全部暴露人群,恶性肿瘤发生率与在24周对照期的结果一致"}], "language": 3}